Valneva Future Growth
Future criteria checks 5/6
Valneva is forecast to grow earnings and revenue by 50.9% and 20.8% per annum respectively. EPS is expected to grow by 55.8% per annum. Return on equity is forecast to be -17.9% in 3 years.
Key information
50.9%
Earnings growth rate
55.8%
EPS growth rate
Biotechs earnings growth | 19.6% |
Revenue growth rate | 20.8% |
Future return on equity | -17.9% |
Analyst coverage | Good |
Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 322 | -15 | 3 | -5 | 7 |
12/31/2025 | 234 | -33 | -2 | -29 | 9 |
12/31/2024 | 192 | 25 | -14 | 9 | 7 |
12/31/2023 | 154 | -101 | -217 | -203 | N/A |
9/30/2023 | 223 | -113 | -208 | -193 | N/A |
6/30/2023 | 431 | -7 | -231 | -211 | N/A |
3/31/2023 | 373 | -135 | -266 | -243 | N/A |
12/31/2022 | 361 | -143 | -275 | -245 | N/A |
9/30/2022 | 439 | 73 | -195 | -149 | N/A |
6/30/2022 | 304 | -159 | -177 | -108 | N/A |
3/31/2022 | 347 | -72 | -83 | 2 | N/A |
12/31/2021 | 348 | -73 | -16 | 77 | N/A |
9/30/2021 | 121 | -248 | 15 | 97 | N/A |
6/30/2021 | 110 | -125 | 51 | 109 | N/A |
3/31/2021 | 98 | -91 | 147 | 182 | N/A |
12/31/2020 | 110 | -64 | 118 | 138 | N/A |
9/30/2020 | 104 | -62 | 67 | 78 | N/A |
6/30/2020 | 120 | -25 | 97 | 105 | N/A |
3/31/2020 | 127 | -8 | -7 | 3 | N/A |
12/31/2019 | 126 | -2 | -5 | 6 | N/A |
9/30/2019 | 116 | 4 | 0 | 10 | N/A |
6/30/2019 | 109 | 1 | 10 | 16 | N/A |
3/31/2019 | 116 | 7 | 14 | 17 | N/A |
12/31/2018 | 113 | 3 | 13 | 16 | N/A |
9/30/2018 | 107 | -7 | 4 | 6 | N/A |
6/30/2018 | 110 | -7 | 8 | 10 | N/A |
3/31/2018 | 108 | -8 | 2 | 5 | N/A |
12/31/2017 | 105 | -11 | 9 | 13 | N/A |
9/30/2017 | 103 | -11 | N/A | 17 | N/A |
6/30/2017 | 100 | -14 | N/A | 19 | N/A |
3/31/2017 | 102 | -46 | N/A | 25 | N/A |
12/31/2016 | 98 | -49 | N/A | 7 | N/A |
9/30/2016 | 93 | -63 | N/A | 4 | N/A |
6/30/2016 | 96 | -61 | N/A | -5 | N/A |
3/31/2016 | 89 | -35 | N/A | -17 | N/A |
12/31/2015 | 83 | -21 | N/A | -20 | N/A |
9/30/2015 | 74 | -16 | N/A | -24 | N/A |
6/30/2015 | 65 | -13 | N/A | -19 | N/A |
3/31/2015 | 55 | -9 | N/A | -15 | N/A |
12/31/2014 | 42 | -26 | N/A | -15 | N/A |
9/30/2014 | 41 | -21 | N/A | -6 | N/A |
6/30/2014 | 43 | -28 | N/A | -21 | N/A |
3/31/2014 | 41 | -29 | N/A | -27 | N/A |
12/31/2013 | 36 | -24 | N/A | -21 | N/A |
9/30/2013 | 26 | -22 | N/A | -27 | N/A |
6/30/2013 | 13 | -14 | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0OB3 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: 0OB3 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0OB3 is expected to become profitable in the next 3 years.
Revenue vs Market: 0OB3's revenue (20.8% per year) is forecast to grow faster than the UK market (3.4% per year).
High Growth Revenue: 0OB3's revenue (20.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0OB3 is forecast to be unprofitable in 3 years.